|
Molecular properties generated using the CDK |
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes (source: FDA (2013)) |
IUPAC Name ![]() |
| 2-[3-(18F)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 9169 | flutemetamol (18F) |
Synonyms ![]() |
| 18F-flutemetamol |
| [18F]flutemetamol |
| flutemetamol F18 |
Database Links ![]() |
|
| CAS Registry No. | 765922-62-1 (source: SciFinder) |
| ChEMBL Ligand | CHEMBL2042122 |
| PubChem CID | 15950376 |
| Search Google for chemical match using the InChIKey | VVECGOCJFKTUAX-HUYCHCPVSA-N |
| Search Google for chemicals with the same backbone | VVECGOCJFKTUAX |
| Search PubMed clinical trials | flutemetamol |
| Search PubMed titles | flutemetamol |
| Search PubMed titles/abstracts | flutemetamol |
| Wikipedia | Flutemetamol (18F) |
| Comments |
| Flutemetamol F-18 (Vizamyl GE Healthcare) is a positron emission tomography (PET) radiotracer approved in 2013 that binds to amyloid plaques in Alzheimer's disease neurodegeneration. However imaging agents have been granted only narrow approval since they can not be used to definitively diagnose Alzheimer's disease or to gauge treatment effectiveness, only to support other diagnostic criteria [2]. |